Pubblicazioni

La Fondazione Progetto Ematologia ha consentito di attuare progetti a livello sopranazionale, sostenendo i collegamenti con importanti centri internazionali, che hanno portato a numerose pubblicazioni sulle maggiori riviste scientifiche internazionali del settore.
All’interno dei circa 450 articoli prodotti dal suo Direttore Scientifico, la Fondazione ha collaborato per quanto riguarda la ricerca bibliografica e l’attività redazionale ad almeno 60 pubblicazioni.

Sono risultate particolarmente importanti tre iniziative sostenute dalla Fondazione Progetto Ematologia, che hanno consentito di standardizzare i criteri di diagnosi, la terminologia e la classificazione dei sintomi di importanti malattie quali le malattie emorragiche congenite e la piastrinopenia immune. Le risultanze di queste collaborazioni internazionali trovano documentazione nelle seguenti pubblicazioni:
–         Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group.
(Blood 2013; 121:2596-2606);
–         ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. 
(Journal Thrombosis and  Haemostasis 2010; 9: 2063-5);
–        Standardization of terminology, definitions and out come criteria in immune  thrombocytopenic purpura af adults and children: report from an international working group. 
(Blood 2009;113: 2386-2393);
in calce alle quali viene espressamente ringraziata la Fondazione Progetto Ematologia.

 

Queste le pubblicazioni fino ad oggi supportate da FPE:

2023

• Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion
  (Ther Adv Hematol. 2023 Feb 28;14:20406207221147777)

• Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in Italy  
  (Mediterr J Hematol Infect Dis. 2023 Mar 1;15(1):e2023019)

• Recent progress in ITP treatment
  (Int J Hematol. 2023 Mar;117(3):316-330)

• Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial  
  (Lancet. 2023 Sep 28:S0140-6736(23)01460-5)

2022

• Thrombopoietin receptor agonist in chemotherapy-induced thrombocytopenia
  (Lancet Haematol. 2022 Mar;9(3):e168-e169)

• Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia  
  (Clin Pharmacol Ther. 2022 Apr;111(4):939-949)

• Registries in immune thrombocytopenia (ITP) in Europe the European Research Consortium on ITP (ERCI) network
  (Br J Haematol. 2022 Jun;197(5):633-638)

• Introduction to a review series on the treatment of thrombocytopenic disorders something old, something new
  (Haematologica. 2022 Jun 1;107(6):1239-1242)

2021

• International survey on Helicobacter pylori testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee
  (Journal of Thrombosis and Haemostasis, 2021 Jan;19(1):287-296)

• Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study  
  (Br J Haematol. 2021 Apr;193(2):386-396)

• Immune thrombocytopenia in myeloid and lymphoid clonal disorders an intriguing association
  (Haematologica 2021 May 1;106(5):1231-1233)

• Practical Recommendations for the Management of Patients with ITP During the COVID-19 Pandemic
  (Mediterr J Hematol Infect Dis. 2021 May 1;13(1):e2021032)

• Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia
  (Blood. 2021 Aug 19;138(7):571-583)

• A new enemy is emerging in the fight against the SARS-CoV-2 pandemic  
  (Haematologica. 2021 Aug 1;106(8):2040-2041)

• Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology
  (J Thromb Haemost 2021 Sep;19(9):2348-2354)

• Thrombosis in immune thrombocytopenia – current status and future perspectives
  (Br J Haematol 2021 Sep;194(5):822-834)

• Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia
  (Clin Pharmacol Ther 2022 Apr;111(4):939-949)

 

2020

• Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years
  (Thromb Res 2020 Jan;185:88-95)

• Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning  
  (Br J Haematol 2020 Sep;190(5):e304-e307)

• Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia
  (Expert Rev Hematol 2020 Dec;13(12):1319-1332)

• Cerebral microbleeds in ITP: alarming or innocent?
  (Blood 2020 Dec 17;136(25):2842-2844)

2019

• Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study
  (Blood 2019 Nov 14;134(20):1708-1711)

• Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report  
  (Hemasphere 2019 Sep 17;3(4):e286)

• Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years
  (Thromb Res 2020 Jan;185:88-95)

• Updated international consensus report on the investigation and management of primary immune thrombocytopenia
  (Blood Adv 2019 Nov 26;3(22):3780-3817)

• Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper
  (Blood Cancer J 2019 Aug 8;9(8):61)

• Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia  
  (Leukemia 2019 Jul;33(7):1598-1607)

• Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies
  (Br J Haematol 2019 May;185(3):503-513)

• Thrombopoietin receptor agonists ten years later
  (Haematologica 2019 Jun;104(6):1112-1123)

2018

• A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP
  (Br J Haematol 2018 Apr;181(2):183-195)

• Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia  
  (J Hematol 2018 Sep;7(3):87-95)

• High-throughput immunophenotypic characterization of bone marrow- and cord blood-derived mesenchymal stromal cells reveals common and differentially expressed markers: identification of angiotensin-converting anzyme (CD143) as a marker differentially expressed between adult and perinatal tissue sources
  (Stem Cell Res Ther 2018 Jan 16;9(1):10)

• The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B 2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting
  (Blood Cancer J 2018 Jun 1;8(6):49)

• Thrombopoietin receptor agonists in hereditary thrombocytopenias
  (J Thromb Haemost 2018 Sep;16(9):1700-1710)

2017

• The cytotoxic action of the CD56+ fraction of cytokine-induced killer cells against a K562 cell line is mainly restricted to the natural killer cell subset
  (Blood Transfus 2017 Jan;15(1):93-100)

• Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia  
  (Haematologica 2017 Aug;102(8):1342-1351)

• ITP and thrombosis an intriguing association
  (Blood Adv 2017 Nov 14;1(24):2280)

• Generation of mesenchymal stromal cells from cord blood evaluation of in vitro quality parameters prior to clinical use
  (Stem Cell Res Ther 2017 Jan 24;8(1):14)

• Beyond immune thrombocytopenia the evolving role of thrombopoietin receptor agonists
  (Ann Hematol 2017 Sep;96(9):1421-1434)

• A hit to current hit wisdom A century later, it’s time for a change  
  (Am J Hematol 2017 Aug;92(8):727-729)

2016

• Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future
  (Stem Cell Res Ther 2016 Jul 13;7(1):93)

• Heterogeneity of Specific CD4+ and CD8+ T Cells Stimulated by CMV pp65 and IE1 Antigens  
  (J Immunother Nov/Dec 2016;39(9):329-342)

• Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease
  (Am J Hematol 2016 Oct;91(10):995-1001)

• Evans syndrome secondary to chronic lymphocytic leukaemia presentation, treatment, and outcome
  (Ann Hematol 2016 May;95(6):863-70)

• Enumeration of residual white blood cells in leukoreduced blood products Comparing flow cytometry with a portable microscopic cell counter
  (Transfus Apher Sci 2016 Apr;54(2):266-70)

 

2015

• Treatment of immune thrombocytopenia in adults the role of thrombopoietin-receptor agonists
  (Semin Hematol 2015 Jan;52(1):16-24)

• Evaluation of lymphocytes inactivation by extracorporeal photopheresis using tetrazolium salt based-assay  
  (Transfus Apher Sci 2015 Oct;53(2):242-5)

• Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival
  (Oncotarget 2015 Jul 30;6(21):18653-63)

 

 

2014

• Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors
  (J Thromb Haemost 2014 Aug;12(8):1266-73)

• Multivariate statistical data analysis as a tool to analyze ex vivo expansion dynamics of cytokine-induced killer cells  
  (Cytometry B Clin Cytom 2014 Jul;86(4):257-62)

• Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia
  (Haematologica 2014 May;99(5):881-7)

• Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C?
  (Leuk Lymphoma 2014 Jun;55(6):1261-5)

• Autoimmune cytopenias in chronic lymphocytic leukemia
  (Am J Hematol 2014 Nov;89(11):1055-62)

• Absence of micronucleus formation in CHO-K1 cells cultivated in platelet lysate enriched medium  
  (Exp Toxicol Pathol 2014 Mar;66(2-3):111-6)

 

2013

• The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia
  (Am J Hematol 2013 Apr;88(4):289-93)

• Standardization of bleeding assessment in immune thrombocytopenia report from the International Working Group  
  (Blood 2013 Apr 4;121(14):2596-606)

• Production of human platelet lysate by use of ultrasound for ex vivo expansion of human bone marrow-derived mesenchymal stromal cells
  (Cytotherapy 2013 Aug;15(8):920-9)

• Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia
  (Am J Hematol 2013 Apr;88(4):277-82)

• Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation
  (J Clin Oncol 2013 Apr 10;31(11):1442-9)

2012

• Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index a prospective, multicenter GITMO study
  (Blood 2012  Aug 9;120(6):1327-33)

• The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines  
  (Blood Cells Mol Dis 2012 Jan 15;48(1):68-75)

• Isolated erythrocytosis study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene
  (Haematologica 2012 Jan;97(1):123-7)

• Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptor
  (Clin Cancer Res 2012 Apr 1;18(7):1870-8)

• Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines
  (Leuk Lymphoma 2012 Nov;53(11):2262-8)

• A study on mutual interaction between cytokine induced killer cells and umbilical cord-derived mesenchymal cells: Implication for their in-vivo use  
  (Blood Cells Mol Dis 2012 Oct 15-Dec 15;49(3-4):159-65)

 

2011

• Epidermal growth factor, basic fibroblast growth factor and platelet-derived growth factor-bb can substitute for fetal bovine serum and compete with human platelet-rich plasma in the ex vivo expansion of mesenchymal stromal cells  derived from adipose tissue
  (Cytotherapy 2011 Sep;13(8):933-43)

• Effect of platelet lysate on the functional and molecular characteristics of mesenchymal stem cells isolated from adipose tissue  
  (Curr Stem Cell Res Ther 2011 Jun;6(2):105-14)

• Association of plasma fibrinogen, C-reactive protein and G-455A polymorphism with early atherosclerosis in the VITA Project cohort
  (Thromb Haemost 2011 Feb;105(2):329-35)

• Analysis of the oxygen sensing pathway genes in familial chronic myeloproliferative neoplasms and identification of a novel EGLN1 germ-line mutation
  (Br J Haematol 2011 May;153(3):405-8)

2010

• Identical IGHV-D-J gene rearrangement may precede the clinical onset of chronic lymphocytic leukemia by several years
  (Am J Hematol 2010 Nov;85(11):868-71)

• Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status  
  (Haematologica 2010 Jul;95(7):1230-2)

 

2009

• Immune thrombocytopenia in lymphoproliferative disorders
  (Hematol Oncol Clin North Am 2009 Dec;23(6):1261-74)

2008

• Loss of the JAK2 intramolecular auto-inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case od idiopatich erythrocytosis
  (Br J Haematol 2008 Sep;142(6):986-90)

• Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia  
  (Blood 2008 Feb 1;111(3):1110-6)

• Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature
  (Haematologica 2008 Jan;93(1):98-103)

• Hemostatic complications of angiogenesis inhibitors in cancer patients
  (Am J Hematol 2008 Nov;83(11):862-70)

• Flow cytometry in the diagnosis of drug-induced thrombocytopenia: two illustrative cases
  (Am J Hematol 2008 Apr;83(4):326-9)

• Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach  
  (Blood 2008 Apr 15;111(8):3998-4003)

• A new TMHA-DHPLC assay for the rapid mutation screening of JAK2 exon 14 in myeloproliferative disorders
  (Am J Hematol 2008 Jul;83(7):603-4)

2007

• Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation
  (Leukemia 2007 May;21(5):1099-103)

• How to estimate bleeding risk in mild bleeding disorders  
  (J Thromb Haemost 2007 Jul;5 Suppl 1:157-66)